Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) reported corporate updates and financial results for its fiscal first quarter ended June 30, 2026. All IMVT-1402 clinical development timelines remain on track across six indications, including Graves’ disease (GD), myasthenia gravis (MG), CIDP, difficult-to-treat rheumatoid arthritis, Sjögren’s disease and cutaneous lupus erythematosus.
The company plans potentially registrational IMVT-1402 data readouts in GD and MG in 2027, and in CIDP and SjD in 2028, with a CLE proof‑of‑concept readout and D2T RA program update expected in the second half of 2026. As of June 30, 2026, cash and cash equivalents were $797.8 million, which Immunovant says provides runway to the potential commercial launch of IMVT-1402 in GD under its current plan.
For the quarter, R&D expenses were $142.6 million versus $101.2 million a year earlier, while G&A expenses declined to $17.7 million from $26.0 million. Net loss was $153.2 million, or $0.75 per share, compared with $120.6 million, or $0.71 per share, in the prior-year period. Non‑GAAP net loss was $139.4 million, up from $102.1 million. Roivant (Nasdaq: ROIV) will host a conference call and webcast on August 6, 2026, at 8:00 a.m. ET.
Positive
- Cash and equivalents $797.8M at June 30, 2026, with runway to potential IMVT-1402 GD launch under current plan
- G&A expenses down to $17.7M from $26.0M year over year
- Non-GAAP G&A expenses reduced to $11.2M from $15.4M year over year
- IMVT-1402 development timelines on track across six announced autoimmune indications
- Interest income of $7.1M, up from $6.3M in prior-year quarter
Negative
- R&D expenses increased to $142.6M from $101.2M year over year
- Non-GAAP R&D expenses rose to $135.4M from $93.3M year over year
- Net loss widened to $153.2M ($0.75/share) from $120.6M ($0.71/share)
- Non-GAAP net loss increased to $139.4M from $102.1M year over year
- Cash and equivalents declined to $797.8M from $902.1M as of March 31, 2026
- Stockholders’ equity decreased to $735.4M from $852.6M since March 31, 2026
News Explained
As of
Market Reaction – ROIV
Following this news, ROIV has gained 0.98%, reflecting a mild positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $34.94.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Annual earnings report | Positive | +14.9% | Income reversal, cash resources, clinical progress, and major Moderna settlement |
| Nov 10 | Quarterly earnings report | Positive | +2.7% | Clinical milestones and substantial consolidated cash supported the business update |
| Aug 11 | Quarterly earnings report | Negative | -2.8% | Higher expenses and net loss accompanied clinical progress and milestone updates |
| May 29 | Annual earnings report | Positive | +6.4% | Development expansion and repurchase activity accompanied quarterly financial results |
| Feb 10 | Quarterly earnings report | Negative | -0.9% | Large loss and private placement accompanied expansion of pivotal development programs |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-tagged events produced positive 24-hour reactions in four of five cases, with one divergence following a negative reaction.
Key Terms
anti-fcrn medical
proof-of-concept technical
potentially registrational regulatory
non-gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE)
- Current cash balance provides runway to the potential launch of IMVT-1402 in GD
- Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026
DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its first fiscal quarter ended June 30, 2026.
Recent Highlights and Upcoming Milestones:
Immunovant’s development plans for IMVT-1402 remain on track across all six announced indications. The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026. In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG. Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD.
Financial Highlights for Fiscal First Quarter Ended June 30, 2026:
Cash Position: As of June 30, 2026, Immunovant’s cash and cash equivalents totaled
Research and Development Expenses: Research and development (R&D) expenses were
Non-GAAP R&D expenses were
General and Administrative Expenses: General and administrative (G&A) expenses were
Non-GAAP G&A expenses were
Net Loss: Net loss was
Common Stock: As of June 30, 2026, there were 206,264,878 shares of common stock issued and outstanding.
Non-GAAP Financial Measures: In addition to reporting the financial results in accordance with accounting principles generally accepted in the United States of America (GAAP), Immunovant reports certain financial results that differ from what is reported under GAAP. Immunovant believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Immunovant’s business. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, Immunovant’s financial results prepared in accordance with GAAP. Other companies, including companies in Immunovant’s industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Investor Conference Call Information
Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026.
To access the conference call by phone, please register online using this Registrational link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “can,” “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” “intend,” and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include statements regarding Immunovant’s progress towards developing IMVT-1402 across a broad range of indications; Immunovant’s expectations regarding the availability of results of clinical trials of IMVT-1402 and whether those results may be adequate to support registration; and the Company’s beliefs regarding the potential sufficiency of its cash runway. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, regulatory strategy, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of global factors, such as international trade tariffs, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402; Immunovant is at various stages of clinical development for IMVT-1402; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s Annual Report on Form 10-K filed with the SEC on May 20, 2026, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| IMMUNOVANT, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) | |||||||
| Three Months Ended June 30, | |||||||
| 2026 | 2025 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 142,631 | $ | 101,200 | |||
| General and administrative | 17,692 | 26,024 | |||||
| Total operating expenses | 160,323 | 127,224 | |||||
| Interest income, net | (7,095 | ) | (6,337 | ) | |||
| Other income, net | (4 | ) | (1,187 | ) | |||
| Loss before provision for income taxes | (153,224 | ) | (119,700 | ) | |||
| Provision for income taxes | — | 913 | |||||
| Net loss | $ | (153,224 | ) | $ | (120,613 | ) | |
| Net loss per common share – basic and diluted | $ | (0.75 | ) | $ | (0.71 | ) | |
| Weighted-average common shares outstanding – basic and diluted | 205,545,373 | 170,872,994 | |||||
| IMMUNOVANT, INC. Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share data) | |||||||
| June 30, 2026 | March 31, 2026 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 797,798 | $ | 902,110 | |||
| Accounts receivable | 697 | 1,133 | |||||
| Prepaid expenses and other current assets | 52,683 | 45,576 | |||||
| Total current assets | 851,178 | 948,819 | |||||
| Property and equipment, net | 351 | 443 | |||||
| Other assets | 961 | 7,752 | |||||
| Total assets | $ | 852,490 | $ | 957,014 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 10,138 | $ | 7,541 | |||
| Accrued expenses and other current liabilities | 106,964 | 96,881 | |||||
| Total current liabilities | 117,102 | 104,422 | |||||
| Total liabilities | 117,102 | 104,422 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Series A preferred stock, par value | — | — | |||||
| Preferred stock, par value | — | — | |||||
| Common stock, par value | 20 | 20 | |||||
| Additional paid-in capital | 2,632,996 | 2,596,971 | |||||
| Accumulated other comprehensive income | 725 | 730 | |||||
| Accumulated deficit | (1,898,353 | ) | (1,745,129 | ) | |||
| Total stockholders’ equity | 735,388 | 852,592 | |||||
| Total liabilities and stockholders’ equity | $ | 852,490 | $ | 957,014 | |||
| IMMUNOVANT, INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited, in thousands) | |||||||||||
| Three months ended June 30, | |||||||||||
| Note | 2026 | 2025 | |||||||||
| Net loss: | $ | (153,224 | ) | $ | (120,613 | ) | |||||
| Adjustments | |||||||||||
| Research and development: | |||||||||||
| Stock-based compensation | (1 | ) | 7,254 | 7,865 | |||||||
| General and administrative: | |||||||||||
| Stock-based compensation | (1 | ) | 6,520 | 10,645 | |||||||
| Estimated income tax impact from adjustments | — | 42 | |||||||||
| Adjusted net loss (Non-GAAP) | $ | (139,450 | ) | $ | (102,061 | ) | |||||
| Three months ended June 30, | |||||||||
| Note | 2026 | 2025 | |||||||
| Research and Development Expenses | $ | 142,631 | $ | 101,200 | |||||
| Adjustments: | |||||||||
| Stock-based compensation | (1 | ) | 7,254 | 7,865 | |||||
| Adjusted research and development expenses (Non-GAAP) | $ | 135,377 | $ | 93,335 | |||||
| Three months ended June 30, | |||||||||
| Note | 2026 | 2025 | |||||||
| General and Administrative Expenses | $ | 17,692 | $ | 26,024 | |||||
| Adjustments: | |||||||||
| Stock-based compensation | (1 | ) | 6,520 | 10,645 | |||||
| Adjusted general and administrative expenses (Non-GAAP) | $ | 11,172 | $ | 15,379 | |||||
(1) Represents non-cash stock-based compensation expense
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
